Tag: GlobeNewswire

Pentagon plans for a new Autonomous Warfare Command and Project Agincourt highlight growing U.S. defense focus on drones, AI, autonomous systems and resilient power infrastructure

Intelligence alone is not enough as autonomous systems move from experimentation toward persistent real-world deployment. Autonomous systems also need power, endurance, resilience, and infrastructure.

MIAMI, Oct. 07, 2026 (GLOBE NEWSWIRE) — AIBotics, Inc. (OTCID: AIBT) (“AIBotics” or the “Company”) today highlighted the growing strategic importance of power, endurance and infrastructure for autonomous systems following the U.S. Department of Defense’s announcement of plans to establish a new Autonomous Warfare Command focused on accelerating autonomous and robotic capabilities across the U.S. military. As previously announced, AIBotics has entered into an Exchange Agreement to acquire Empulser Enterprises LLC (“Empulser”), a U.S. defense-technology company developing wireless power and autonomous-system technologies, subject to customary closing conditions.

In his inaugural “State of the Force” address, Secretary of Defense Pete Hegseth announced plans to establish a new four-star Autonomous Warfare Command to accelerate the development and fielding of autonomous and semi-autonomous systems across the U.S. military. He also unveiled Project Agincourt, an interim initiative designed to bring military operators and technology entrepreneurs together to speed development and adaptation of AI- and drone-enabled capabilities.

The initiatives reflect an accelerating Department of Defense emphasis on unmanned systems, artificial intelligence and autonomy across aerial, maritime and ground operations. Separately, the Pentagon also announced an initiative to strengthen the ability of military installations to generate and maintain resilient power independently of vulnerable public grids.

For AIBotics and Empulser, these developments highlight a broader challenge they believe will become increasingly important as autonomous systems move from experimentation toward persistent real-world deployment: intelligence alone is not enough. Autonomous systems also need power, endurance, resilience, and infrastructure.

Power. Persistence. Autonomy.

Empulser is developing a U.S.-focused defense and dual-use technology platform around wireless power, autonomous systems, unmanned technologies, and supporting infrastructure.

Its development strategy is focused on technologies intended to improve the endurance, deployment, and coordination of autonomous platforms across defense, government, critical-infrastructure, and commercial applications.

The company’s long-term technology thesis is centered on three interconnected requirements:

1. Power. Autonomous platforms require reliable energy systems capable of supporting operations beyond conventional manual charging cycles.
2. Persistence. Extending the time autonomous systems can remain operational can increase their usefulness across surveillance, inspection, logistics, security, and other applications.
3. Autonomy. AI-enabled systems become increasingly valuable as they can perform missions with progressively less human intervention while coordinating with other machines and infrastructure.

Empulser’s technology roadmap includes wireless-power systems, charging infrastructure, autonomous aerial and ground platforms, AI-enabled fleet coordination and related technologies intended to support more persistent unmanned operations. The company’s investor materials describe a modular architecture spanning energy, infrastructure, intelligence, platforms and software.

Patrick Tsang, Founder and Chief Executive Officer of Empulser and Strategic Advisor to AIBotics, said, “The acceleration of autonomous systems across defense makes the power and persistence problem increasingly important. Building a more capable drone or robot is only part of the equation. If autonomous machines are going to operate for longer periods, across more demanding environments and with less human intervention, they will need an infrastructure layer capable of supporting them.” Mr. Tsang continued, “That is the challenge Empulser is being built around. Our ambition is to combine wireless power, autonomous systems and enabling technologies to increase the persistence and effectiveness of unmanned platforms. Ultimately, we want to help move the industry toward a future where flight time and battery endurance become less significant constraints on autonomous operations.”

Ben Kaplan, Chief Executive Officer of AIBotics, commented, “The direction of the autonomous-systems market is becoming increasingly clear. Artificial intelligence is moving from software into machines operating in the physical world, and those machines need power, communications, coordination and infrastructure. Empulser’s focus on power and persistence gives AIBotics exposure to an important layer of that emerging ecosystem.”

Mr. Tsang added, “AI gives machines intelligence. Power gives them persistence. Infrastructure enables autonomy at scale. The Pentagon’s growing focus on autonomous warfare capabilities and resilient power infrastructure underscores how closely those two challenges are converging. That intersection, power, persistence and autonomy, is exactly where I believe Empulser’s strategy becomes most compelling.”

From Intelligent Machines to Persistent Autonomous Systems

The Department of Defense’s evolving autonomy strategy encompasses more than drones. Current military initiatives include autonomous aircraft, unmanned maritime platforms, AI-enabled command-and-control systems and other robotic capabilities. The Pentagon has said the planned Autonomous Warfare Command is intended to accelerate autonomous capabilities across the joint force.

Empulser similarly views autonomy as a broader systems challenge rather than a single-platform opportunity. The company’s development strategy contemplates applications across autonomous aerial systems, unmanned ground vehicles, fleet-management software, wireless charging infrastructure and related defense and dual-use technologies. Potential applications identified by Empulser include persistent surveillance, perimeter security, autonomous inspection, logistics, infrastructure monitoring and coordinated unmanned operations.

Empulser’s products and technologies remain in development. Technology performance, testing, validation, certification, customer adoption and commercialization remain subject to successful engineering, financing and execution.

About AIBotics

AIBotics, Inc. is a global technology company building a platform around AI-enabled robotics, autonomous systems and intelligent automation. The Company focuses on applying advanced technologies to real-world environments through strategic partnerships, technology development and international market relationships. AIBotics seeks to identify, develop, implement, and scale solutions that improve how machines operate, automate business processes, and extend the practical application of artificial intelligence into the physical world. Through a scalable, partnership-driven model, AIBotics is building a diversified robotics and autonomous-systems platform designed to support commercial, industrial and other mission-driven applications across global markets. For more information on AIBotics, visit www.aibotics.ai

About Empulser Enterprises LLC

Empulser Enterprises LLC is a U.S.-focused defense and dual-use technology company developing a platform around wireless power, autonomous systems, unmanned technologies, and supporting infrastructure. Empulser’s development strategy is focused on technologies intended to improve the endurance, deployment, and coordination of autonomous platforms across defense, government, critical-infrastructure, and commercial applications. Empulser’s products and technologies are in development, and future milestones are subject to successful engineering, testing, validation, certification, funding and commercialization. For more information on Empulser, visit www.empulser.com.

About Patrick Tsang

Patrick Tsang is an international investor and entrepreneur and Chairman of Tsang Group, a fourth-generation single-family office with interests across technology, real estate and natural resources. He is the Founder and Chief Executive Officer of Empulser Enterprises LLC, a U.S.-focused defense and dual-use technology company developing technologies around wireless power, autonomous systems and unmanned platforms.

Over more than two decades, Tsang has worked across international investment, capital formation, mergers and acquisitions, corporate development and emerging technology, building relationships across Asia, Europe, the Middle East and North America. Through his leadership, he was an early-stage investor and strategic advisor to Pulse Evolution, playing a strategic role in its journey through the FaceBank/fuboTV transaction and subsequent NYSE listing during the Covid period. SEC filings subsequently referenced an approximately 300-times return in two years on the investment based on fuboTV’s late-2020 share price.

Tsang is a qualified solicitor in England and Wales and Hong Kong and attended Harvard Business School’s Owner/President Management (OPM) program. He is the author of The Global Citizen and has been actively involved in philanthropy and international leadership throughout his career, including through the Duke of Edinburgh’s World Fellowship, Rotary International and YPO. He was recognized as China Economic Person of the Year during the China Economic Development Forum in 2014.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, among other things, statements regarding the proposed acquisition of Empulser; the anticipated structure, timing, closing and benefits of the transaction; the issuance, earning and conversion of Series C Preferred Stock and potential dilution associated with conversion; the achievement and verification of earn-out milestones; any discretionary pre-closing loans by AIBotics to Empulser; the contemplated management transition involving Patrick Tsang; AIBotics’ and Empulser’s business strategies; technology development, testing, validation, certification and commercialization; intellectual-property development; financing and capital formation; strategic partnerships; government, defense and commercial opportunities; potential customers, contracts and revenue; future acquisitions; and the Company’s broader strategy in AI, robotics, autonomous systems and defense and dual-use technology. Forward-looking statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the possibility that the transaction may not close on the anticipated terms or timing, or at all; failure to satisfy or waive closing conditions, including delivery of required audited financial statements and maintenance of required filing status; termination following due diligence, an uncured material breach or a material adverse change; AIBotics’ decision not to provide discretionary pre-closing financing or the parties’ failure to execute satisfactory loan and security documents; failure to achieve or substantiate earn-out milestones; setoff or cancellation of earn-out consideration; dilution associated with conversion of preferred stock; failure to satisfy the conditions to Patrick Tsang’s proposed appointment as Chief Executive Officer and a director; integration risks; development and engineering risks; testing, certification and regulatory requirements; protection of intellectual property; competition; dependence on key personnel and strategic relationships; customer adoption; government procurement processes; and the Company’s ability to execute its business plan. Readers should review AIBotics’ filings with the U.S. Securities and Exchange Commission, including the Current Report on Form 8-K relating to the Exchange Agreement, for additional information concerning risks and uncertainties. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

Media and Investor Relations

David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 Office
(404) 281-8556 Mobile and WhatsApp
dk@atlcp.com

Company Advances R3ALM Ecosystem Toward Commercial Launch and Announces Multiple Tokenization Projects

BOSTON, MA, Oct. 07, 2026 (GLOBE NEWSWIRE) — Vystar Corporation (OTCQB: VYST) today announced that, following the joint acquisition of The R3ALM Ecosystem, Vystar and its co-owner have completed the formation of the new operating corporation and appointed its joint Board of Directors.

At the same time, the R3ALM technical team has been advancing the platform from its test-server environment toward live deployment, with several of the remaining modules now being prepared for launch.

A Platform Designed Across Multiple Markets

R3ALM.com is being developed as a 22-module financial and commerce ecosystem rather than a single-purpose tokenization platform. Its architecture is designed to connect activities that traditionally operate across separate systems, including:

• Digital capital formation and investor access
• Tokenized real-world assets and digital securities infrastructure
• AI-assisted decision intelligence with human approval controls
• Identity, eligibility, wallets and transaction records
• Trading, liquidity, treasury and market-data tools
• Collectibles, private assets and other specialized markets
• Business-to-business and business-to-consumer participation

The commercial objective is to create a more connected environment in which discovery, diligence, participation, transactions and supporting evidence can operate through a common technology infrastructure.

As development continues, these shared capabilities are intended to support multiple customer and market applications rather than limiting R3ALM to a single product category.

Multiple Tokenization Projects Under Development

Vystar and R3ALM have also secured multiple projects involving tokenization and digital commerce across the collectibles, entertainment and financial sectors.

Over the coming weeks, the companies expect to provide additional information regarding these projects, including the underlying business models, the role of R3ALM technology and the potential revenue opportunities associated with each project.

Management believes these projects can serve as important proof-of-concept applications for the broader R3ALM Ecosystem by demonstrating how tokenization can be combined with digital commerce, customer engagement and additional revenue-generating capabilities.

The R3ALM architecture is being developed to support ecommerce environments that can incorporate digital currencies alongside social-media engagement, marketing, VIP live and digital experiences, memorabilia and collectible sales, and other specialized commercial applications.

Multiple Potential Revenue Streams

A key component of the R3ALM strategy is the ability to combine multiple commercial activities within a single ecosystem.

Bernie O’Neil, Managing Director of R3ALM, stated:

“What is most important to Vystar and R3ALM, as well as our clients, is the ability of the ecosystem to create additional opportunities for revenue generation and financing. By connecting tokenization with ecommerce, digital assets, marketing, customer engagement and other commercial activities, we believe R3ALM can provide clients with capabilities that extend well beyond simply creating a token.”

Under the arrangements currently being developed, Vystar and R3ALM will participate economically in certain projects through ownership interests, participation in digital assets or currencies, and shares of revenue generated from multiple services and commercial activities.

Management believes this project-based approach has the potential to create a diversified revenue model in which R3ALM participates not only in the technology infrastructure but also, where appropriate, in the economic activity generated through the ecosystem.

Building Toward Commercial Launch

With the new corporation established, the joint Board appointed and the technical team progressing toward live deployment, Vystar believes R3ALM is moving from development and testing toward the next phase of its business strategy.

The Company expects to provide additional announcements as individual R3ALM projects progress and additional platform modules move into production.

# # #

About Vystar Corporation

Vystar Corporation is focused on identifying and advancing strategic opportunities that can enhance shareholder value and expand the Company’s participation in high-potential innovation markets. Through this proposed transaction with R3alm, Vystar is seeking to establish a meaningful position in the evolution of digital finance, tokenized assets, intelligent trust systems and modern capital markets infrastructure.

About R3alm

R3alm is building a compliance-focused AI and Web3 ecosystem designed to connect capital formation, tokenized assets, investor access, digital finance infrastructure, trust systems and intelligent automation. Its broader platform vision is intended to support both enterprise and consumer participation in the next generation of financial markets.

Vytex – Allergy Free Natural Rubber Latex – The Company owns the formulations and intellectual property that creates what Vystar believes to be the highest quality products as against any competitor’s products in many cases at better pricing. By way of example, Vystar can manufacture allergy and ammonia free natural latex products ranging from foam utilized in pillows, mattresses and toppers, to gloves, condoms and other products. The Company believes its FDA approved products are unrivaled in the industry. Vystar fortunately has a large combined inventory of thousands of pillows and mattress toppers warehoused in the United States.

RXAIR – Vystar owns the patents and has achieved FDA approval, as well as EPA, CARB and other air purification certifications. We have built a line of products for the home and medical facilities. The product lines range from a personal $500 unit to an industrial $6,000 unit for hospitals or similarly situated medical services. Vystar has sold more than 20,000 residential and 400 hospital units. Vystar sells replacement cartridges. Each cartridge lasts about 1 year and this should yield a very lucrative revenue stream.

In addition, Vystar has invested $500,000 in manufacturing and high-speed tooling for the units. These units are built to eliminate germs, viruses and bacteria. Vystar maintains a stockpile of more than a thousand units and replacement cartridges. Also important, Vystar is under a medical device exemption from the recent tariffs.

FEC – The Hughes Reactor changes flow of liquid or gas into sound waves. The sound can be brought to powerful levels using a mechanism that has no moving parts. This allows the reactor the ability to harness the energy into various uses. The uses for this patented technology include: Flow Meter, hard water abatement, air purification, multiple dialysis applications and combustion enhancements for natural gas, biofuels, gasoline. This energy is powerful, clean, and controllable. It can be used to measure flow, to push forward chemical reactions such as combustion, or to mix chemicals together thoroughly and instantly. All of this technology is protected by Vystar’s intellectual property.

Forward-Looking Statements

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

This press release contains forward-looking statements within the meaning of applicable securities laws. Such statements include, but are not limited to, statements regarding the proposed transaction with R3alm, Inc. and RXAIR, anticipated strategic benefits, the development of the R3alm ecosystem, the proposed R3EQ equity token, future product and platform capabilities, capital markets opportunities, market adoption, regulatory positioning and expected long-term value creation. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Vystar undertakes no obligation to update any forward-looking statements except as required by law.

Important Information

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities, tokens or investment products in any jurisdiction. Any such offering, if made, will be made only pursuant to definitive offering materials and in compliance with applicable law.

Investor / Media Contact
Vystar Corporation
Investor Relations: https://vystarcorp.com/investor-relations
Company websites: https://r3alm.com
Media & Investors: Jamie Rotman – jrotman@vytex.com
Partnerships 1(508)791-9114

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has entered into agreements to partner with Wittington Investments, Limited (“Wittington”), the holding company of the Weston family based in Canada, to acquire from The Boots Group the Boots retail operations in the UK and Ireland, the Boots Opticians business, the No7 Beauty Company, and Boots’ Thailand and franchised businesses (collectively, “Boots”) for a total purchase price of approximately US$8.9 billion (inclusive of assumed debt) (the “Transaction”).

“We are very pleased to partner with Galen Weston and the Wittington team to acquire Boots, a leading historic brand in the UK and Ireland,” said Prem Watsa, Chairman and Chief Executive Officer of Fairfax. “For many years, the Westons have grown and developed some of the most successful retail brands in Canada, including in pharmacy and beauty, and we are very confident that Wittington will be an excellent steward of the Boots business and a terrific partner to Fairfax.”

“Boots is one of Britain’s most enduring businesses, with a rich heritage, a trusted name and a vital role in everyday life across the UK and Ireland,” said Galen Weston. “We have great respect for Boots’ legacy and leading market position. We see a meaningful opportunity to make a great business even better, through stable, long-term ownership, further capital investment and renewed operating focus required to serve customers with excellence for generations to come. We are delighted to partner with Fairfax, which brings an extensive track record of long-term investing in leading retail brands, and shares our conviction in Boots’ future.”

In connection with the Transaction, Fairfax entered into an equity commitment letter pursuant to which it has agreed to provide, or cause an affiliate of it to provide, up to approximately US$2.3 billion for the purposes of satisfying the purchase price to be paid for Boots. Following the closing of the Transaction, it is expected that Fairfax will own 50% of the equity of Boots, with Wittington having operational control and Galen Weston serving as Chair of Boots. The Transaction is subject to customary closing conditions and is expected to be completed in the first quarter of 2027. The transaction does not include The Boots Group’s other interests in Farmacias Benavides and Alliance Healthcare Deutschland which will be retained by their current owner.

Wittington Investments, Limited is the private holding company for the Weston family based in Canada. It is the controlling shareholder of George Weston Limited – and through it, Loblaw Companies Limited and Choice Properties. With more than 2,800 locations, Loblaw is Canada’s largest grocery retailer and owns Shopper Drug Mart, the nation’s largest pharmacy, health and beauty business. Choice Properties, Canada’s largest Real Estate Investment Trust (REIT), has a portfolio comprised of approximately 700 high-quality properties across three strategic asset classes, including 44.6 million square feet of necessity-based retail.

Fairfax is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management.

For further information contact:	John Varnell, Vice President, Corporate Development
	at (416) 367-4941

Certain statements contained herein may constitute “forward-looking statements” and are made pursuant to the “safe harbour” provisions of applicable Canadian and U.S. securities laws. Such forward-looking statements may include, among other things, statements regarding the Transaction, the timing of completion thereof and expectations regarding future performance of Boots. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Fairfax to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the failure to successfully complete the Transaction on the terms and timeframes contemplated; our ability to complete acquisitions and other strategic transactions on the terms and timeframes contemplated, and to achieve the anticipated benefits therefrom; a reduction in net earnings if our loss reserves are insufficient; underwriting losses on the risks we insure that are higher than expected; the occurrence of catastrophic events with a frequency or severity exceeding our estimates; changes in market variables, including unfavourable changes in interest rates, foreign exchange rates, equity prices and credit spreads, which could negatively affect our operating results and investment portfolio; the cycles of the insurance market and general economic conditions, which can substantially influence our and our competitors’ premium rates and capacity to write new business; insufficient reserves for asbestos, environmental and other latent claims; exposure to credit risk in the event our reinsurers fail to make payments to us under our reinsurance arrangements; exposure to credit risk in the event our insureds, insurance producers or reinsurance intermediaries fail to remit premiums that are owed to us or failure by our insureds to reimburse us for deductibles that are paid by us on their behalf; our inability to maintain our long term debt ratings, the inability of our subsidiaries to maintain financial or claims paying ability ratings and the impact of a downgrade of such ratings on derivative transactions that we or our subsidiaries have entered into; risks associated with implementing our business strategies; the timing of claims payments being sooner or the receipt of reinsurance recoverables being later than anticipated by us; risks associated with any use we may make of derivative instruments; the failure of any hedging methods we may employ to achieve their desired risk management objective; a decrease in the level of demand for insurance or reinsurance products, or increased competition in the insurance industry; the impact of emerging claim and coverage issues or the failure of any of the loss limitation methods we employ; our inability to access cash of our subsidiaries; an increase in the amount of capital that we and our subsidiaries are required to maintain and our inability to obtain required levels of capital on favourable terms, if at all; the loss of key employees; our inability to obtain reinsurance coverage in sufficient amounts, at reasonable prices or on terms that adequately protect us; the passage of legislation subjecting our businesses to additional adverse requirements, supervision or regulation, including additional tax regulation, in the United States, Bermuda, Canada or other jurisdictions in which we operate; risks associated with applicable laws and regulations relating to sanctions, anti-money laundering and corrupt practices in Canada and in foreign jurisdictions in which we operate; risks associated with government investigations of, and litigation and negative publicity related to, insurance industry practice or any other conduct; risks associated with political and other developments in foreign jurisdictions in which we operate; risks associated with legal or regulatory proceedings or significant litigation; failures or security breaches of our computer and data processing systems; the influence exercisable by our significant shareholder; adverse fluctuations in foreign currency exchange rates; our dependence on independent brokers over whom we exercise little control; financial reporting risks relating to deferred taxes associated with amendments to IAS 12 – Income Taxes; impairment of the carrying value of our goodwill, indefinite-lived intangible assets or investments in associates; our failure to realize deferred income tax assets; risks associated with Canadian or foreign tax laws, or the interpretation thereof; technological or other change that adversely impacts demand, or the premiums payable, for the insurance coverages we offer; disruptions of our information technology systems; assessments and shared market mechanisms that may adversely affect our insurance subsidiaries; risks associated with economic disruptions from global conflicts and the development of other geopolitical events worldwide; and risks associated with tariffs, trade restrictions, or other regulatory measures imposed by domestic or foreign governments that may, directly or indirectly, affect our business. Additional risks and uncertainties are described in our most recently issued Annual Report, which is available at www.fairfax.ca and on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov, and in our base shelf prospectus (under “Risk Factors”) filed with the securities regulatory authorities in Canada, which is available on SEDAR+ at www.sedarplus.ca. Fairfax disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson & Johnson, and Genmab and AbbVie.

DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) — (www.247marketnews.com)– For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?

A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These developments span different levels of clinical evidence, from exploratory Phase 2 findings to randomized Phase 3 results and an FDA approval. SEC

24/7 Market News highlights five advances worth following as the year moves into its final quarter, beginning with NeOnc Technologies Holdings and its work in a particularly difficult treatment setting: aggressive brain cancer that has returned after previous therapy.

NeOnc Technologies Holdings (NASDAQ: NTHI): Encouraging Survival Findings Where Better Options Are Urgently Needed

NeOnc stands out in this group for the challenge it is confronting. Recurrent high-grade brain cancer remains an exceptionally difficult treatment setting. The National Cancer Institute notes that recurrent central nervous system tumors are rarely curable, underscoring the importance of developing additional treatment options. Cancer.gov

On August 12, NeOnc reported that patients in its 24-patient Phase 2a study of intranasal NEO100 achieved a median overall survival of 26.09 months. Estimated survival was 60.9% at 12 months and 54.1% at 24 months. Importantly, survival was measured from the first treatment dose following recurrence, not from the original diagnosis. The study involved patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. SEC

The treatment approach is also distinctive. NEO100 is administered intranasally by patients at home and is designed to reach the brain through pathways that bypass the blood-brain barrier, a major obstacle in brain-cancer drug delivery. NeOnc reported predominantly low-grade adverse events and no major toxicities in the cohort. SEC

These findings represent an encouraging survival signal, not a randomized demonstration of improved survival. The study had no concurrent control group, and progression-free-survival findings varied by assessment method, reaching statistical significance against the historical benchmark under RANO 2.0 but not under the original protocol-specified criteria. NeOnc has outlined plans to discuss a registrational development pathway with the FDA. SEC

For a disease setting where treatment options are limited, the combination of observed survival, reported tolerability and an at-home delivery approach makes NEO100 a development worth following as further clinical evaluation proceeds. Cancer.gov

Revolution Medicines (NASDAQ): A Pancreatic-Cancer Advance That Has Already Reached Approval

Revolution Medicines delivered one of the year’s clearest examples of clinical progress translating into an available treatment. On August 26, the FDA approved Rasonque, or daraxonrasib, a targeted therapy for metastatic pancreatic adenocarcinoma. Revolution Medicines

In a randomized study involving 500 previously treated patients, median overall survival reached 13.2 months with Rasonque versus 6.7 months with standard chemotherapy. Unlike an uncontrolled survival observation, this result established a benefit against a treatment comparator within the same trial. U.S. Food and Drug Administration

The approval is particularly meaningful in pancreatic cancer, where aggressive disease, late detection and historically limited treatment options have contributed to poor outcomes. It also provides a concrete example of what successful clinical development can accomplish: moving a promising approach from research into patient care. U.S. Food and Drug Administration

Moderna (NASDAQ) and Merck (NYSE): Personalized Cancer Immunotherapy Reaches a Phase 3 Milestone

Moderna and Merck reported a different kind of advance on August 19: positive Phase 3 results for intismeran autogene, an individualized mRNA-based cancer therapy, combined with Keytruda.

The INTerpath-001 trial demonstrated statistically significant improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone in patients whose high-risk melanoma had been surgically removed. According to the companies, this was the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer treatment. Merck.com

The approach is designed around the characteristics of an individual patient’s tumor. Its promise is not a universal vaccine against cancer, but a more personalized immune response to the disease. Overall-survival follow-up continues, while the companies plan to engage regulators regarding potential submissions. Merck.com

Johnson & Johnson (NYSE): Dual-Target Immunotherapy Delivers Substantial Myeloma Results

On July 23, Johnson & Johnson reported that combining Tecvayli and Talvey in the Phase 3 MonumenTAL-6 trial reduced the relative risk of disease progression or death by 89%, and the relative risk of death by 62%, compared with the study’s standard-treatment options.

The trial involved patients with relapsed or refractory multiple myeloma who had received one to four prior treatment lines. The combination targets two different proteins associated with myeloma cells, BCMA and GPRC5D, directing immune activity against the disease through complementary targets. JNJ.com

The investigational combination’s improvements in both disease control and overall survival support the potential to bring this dual-target approach earlier into treatment. The reported percentages describe relative reductions in risk, not percentages of patients cured. JNJ.com

Genmab (NASDAQ) and AbbVie (NYSE): New Hope in First-Line Aggressive Lymphoma

On October 5, Genmab and AbbVie announced that adding epcoritamab to the standard R-CHOP regimen reduced the relative risk of progression or death by 51% in the Phase 3 EPCORE DLBCL-2 trial.

The reported result applied to newly diagnosed diffuse large B-cell lymphoma patients with International Prognostic Index scores of 2–5. Its importance lies in the possibility of improving treatment at the outset, rather than waiting until the disease returns. AbbVie News Center

The combination remains investigational. The companies plan regulatory discussions and presentation of the findings at a future medical meeting, making this another development to follow beyond its initial announcement. AbbVie News Center

Taken together, these developments offer reasons for optimism without suggesting that every clinical question has been answered. An approved therapy, positive randomized trials and an early survival signal occupy different positions along the development path. Their shared importance is the effort to improve outcomes where existing treatments remain insufficient.

For NeOnc, the coming months also include a confirmed November 17, 2026, FDA End-of-Phase 1 meeting for its separate NEO212 program, covering proposed clinical-development plans and the evidence needed for a potential future marketing application. That meeting is distinct from NEO100’s development discussions and does not itself establish an agreed approval pathway. SEC

The hopeful turn in 2026 is not that cancer has been solved. It is that several approaches are producing evidence worth advancing and, in some cases, treatments patients can already receive.

For patients and families, the ultimate significance is not a company’s size or stock symbol. It is the possibility of more birthdays, more ordinary days, and more time together.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

7 October 2026

Notification no. 79/2026

Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.

In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata.

For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Contact: Stefan Kailay Wind, Nordic Head of Media Relations, tel. +45 45 14 14 00

Attachment

• APMH Invest AS – sale – 2026 10 06

Connex Rewards gives customers instant access to savings, travel, entertainment, more

LITTLE ROCK, Ark., Oct. 07, 2026 (GLOBE NEWSWIRE) — Kinetic, a leading residential and business fiber internet provider, today announced the launch of Kinetic Rewards, a loyalty program that gives customers meaningful savings and benefits across the things they enjoy every day.

Available exclusively through the GoKinetic mobile app, Kinetic Rewards gives customers access to discounts, special offers and experiences. The program was developed in partnership with global loyalty and rewards company TLC Worldwide and is powered by Connex Rewards, the U.S. subsidiary of TIMWETECH.

“Customers want and deserve to receive meaningful, tangible benefits from the brands they do business with,” said Stacie Vongvanith, executive vice president and Kinetic’s chief customer officer. “Kinetic Rewards builds on our Kinetic Promise to provide better Wi-Fi, better value and a better internet experience to help our customers live their best lives. Our customer obsession is real, and our customers are our number one priority; that’s why I’m happy to introduce this effort because it puts benefits back in the hands of our customers. This is internet better.”

Why Kinetic Rewards

This Kinetic Rewards program reflects what customers said they wanted in a recent Kinetic consumer survey: to be recognized for loyalty. Rather than a one-time perk, Kinetic Rewards reframes the relationship with customers as an investment in their everyday lives, one built on continued engagement, recognition, and value.

Customers can save on meals out, family activities, movies, shopping, gifts and wellness experiences through discounts, buy-one-get-one offers, complimentary appetizers and other benefits. Featured brands and destinations available to all customers include Qdoba, AMC Theatres, Costco®, 1-800-Flowers.com®, Harry & David, Walt Disney World®, and Universal Orlando Resort.

In addition to meals and activities, Kinetic Rewards users have the option to explore travel options across more than 700 airlines, cruises and car rentals worldwide. By using Kinetic Rewards, customers can save an average of more than 15% on hotel and resort bookings, with access to multiple travel options.

A Simple, App-First Experience

Kinetic Rewards was intentionally designed to be simple to use and easy to understand:

• Customers enroll through the award-winning GoKinetic app. No additional app or login required.
• Once enrolled, customers immediately gain access to everyday savings, discounts, travel benefits, entertainment offers, wellness rewards, and more.
• The experience is intuitive, transparent, and engaging, giving customers clear visibility into available offers, rewards, and their progress.

For many Kinetic customers, Kinetic Rewards offers a new and meaningful way to get more value from their Kinetic service.

How the Program Works Behind the Scenes

The app curates everyday savings with access to offers from more than 55,000 merchants, discounts, travel benefits, entertainment offers, and wellness rewards, and entertainment perks available to customers.

Connex Rewards provides the program’s technology and personalization capabilities, including segmented and customized offers, gamification and incentives for completing activities.

“We’re excited to partner with Kinetic and Connex Rewards to deliver a best-in-class rewards offering built specifically for telcos,” said Jay Cary, CEO of TLC Worldwide North America. “Kinetic Rewards brings that partnership to life, combining TLC’s unrivaled breadth of rewards with Connex Rewards’ leading technology to make offers easy for customers to discover and use. It gives Kinetic a more powerful way to engage customers and build lasting loyalty.”

Kinetic Rewards is available now to Kinetic customers through the GoKinetic app. To see if Kinetic is available in your area and how to become a customer, visit www.gokinetic.com.

About Kinetic

Named the 2026 Telecommunications Company of the Year (Stevie Gold/American Business Awards), Kinetic is a business unit of Uniti (NASDAQ: UNIT) and a leading provider of multi-gigabit fiber internet, whole-home Wi-Fi, internet security and voice services in 1,400 markets across 18 states in the Southwestern, Southeastern, Midwestern and Northeastern United States. Additional information is available at gokinetic.com.

About TLC Worldwide

TLC Worldwide is a global leader in customer engagement, loyalty and reward solutions. We help the world’s most ambitious brands drive sales, increase engagement and build lasting customer connections through personalized, experience-led programs. With a presence in more than 50 countries and over 30 years of expertise, TLC delivers scalable, data-driven programs that create real impact—on brand, on budget and designed to grow.

About Connex Rewards

Connex Rewards offers a telecom-focused rewards platform powered by the technology and expertise of its parent company, TIMWETECH, which provides products and services to more than 140 telecom carriers globally. The Connex Rewards platform has been deployed with more than a dozen carriers across prepaid and postpaid wireless and home internet services. The platform enables telecom operators to deliver segmented, personalized and gamified rewards experiences that drive engagement, loyalty and customer value.

Media Contacts:

Kinetic: Victoria Carman – Kinetic.PR@uniti.com

TLC Worldwide: Aliza Lalani — Aliza.Lalani@tlcworldwide.com

	●	Service upgrade — tailor-made outreach nursing plus rehabilitation, a full recovery service for seniors
	●	Margin from day one — an already-trading clinic, plus in-house physiotherapy replacing outsourced hours
	●	Premium standard set in Hong Kong, then the same model into Mainland China

Hong Kong, Oct. 07, 2026 (GLOBE NEWSWIRE) — Click Holdings Limited (“Click Holdings” or “Click” or “we” or “us”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), a leader in human resources (“HR”) and senior care solutions in Hong Kong, today announced that Care U, its premium senior-care brand, is adding a live rehabilitation layer and becoming a more complete silver-economy platform. Through a new Hong Kong joint-venture company, Care U Rehabilitation Services Company Limited, an already-operating physiotherapy clinic will continue operating seamlessly as Care U Rehabilitation Centre, which serves as the Group’s Central Clinic (the “Central Clinic”).

This is a brand upgrade, a margin move, and the Hong Kong proof point for Mainland China. Care U’s outreach is not a new physiotherapy desk. It is a long record of one-to-one nursing, home care and medical escort, now joined to a live rehabilitation centre. Together they are a full recovery service: tailor-made nursing plus rehab, in the clinic or at home. Designed rehab packages sit beside the nursing plan. A senior can leave hospital with a Care U escort, start rehab at the centre or at home, and stay on Care U nursing without changing provider.

Three things this does

●		It makes Care U a full recovery service. The depth is outreach nursing, not only physiotherapy. Care U already delivers tailor-made nursing, home care and escort where the senior lives. The Central Clinic adds rehabilitation under the same name — designed packages, clinic sessions and home physiotherapy. Post-stroke rehab and hospital-discharge support are examples of a wider book. Nursing and rehab are planned together, so the client does not change provider between recovery and daily care. Families, insurers and Community Care Service Voucher (“CCSV”) households stay inside Care U from escort and discharge, through clinic or home physiotherapy, and on to nursing.
●		It is expected to lift gross margin from day one. The contributed centre is already trading. Combined with Care U’s existing physiotherapy book and home-visit network, the unit is expected to be cash-generative from Completion. In-house centre sessions and employed physiotherapists replace third-party outsourcing on a growing share of Care U cases. That mix is how management expects Group gross margin to improve as volume moves inside the brand.
●		It sets the premium standard in Hong Kong, then takes it to the Mainland. Pricing, packaging and public materials stay on the Care U tariff. This is not a discount clinic. The Central Clinic is the quality signal for insurer preferred-provider talks, corporate plans and medical referral. Scale is outreach — home visits, CCSV and post-acute care delivered where seniors live. Once that Hong Kong standard is running, the same central-clinic-plus-outreach model is the template for the Greater Bay Area and other Mainland cities, alongside Care U’s existing home-nursing work, including the Shandong MOU announced on 1 September 2026.

CEO Commentary

“Care U’s outreach was built on nursing. That is the experience,” said Mr. Jeffrey Chan, Chief Executive Officer of Click Holdings. “The clinic adds rehabilitation to that nursing, so the senior gets a tailor-made recovery service — nursing and rehab, at home or in the centre — under one name. Post-stroke is one case, not the product. The clinic is already seeing patients. We are not waiting to build it, and we are not discounting it. Keeping that physiotherapy inside the Group is how margin starts from day one.”

“Hong Kong is where we set the standard. Families and insurers get a Care U they can walk into, and most of the hours still go to the client. That is the model we intend to take into Mainland China.”

How it goes live

The clinic is already seeing patients. Upon completion, it will continue operating in the same premises under the Care U name as the Group’s Central Clinic. Care U’s nursing services, home visits, and rehabilitation will then be integrated into a single platform, with employed physiotherapists moving between the clinic and clients. There is no fit-out required, ensuring zero interruption of service.

About Click Holdings Limited (NASDAQ: CLIK)

Click Holdings Limited (NASDAQ: CLIK) is a Hong Kong-based leader in AI-powered human resources and senior care solutions. Through its proprietary platform, CLIK connects clients with a talent pool of over 25,000 professionals, serving nursing, logistics, and professional services sectors.

For more information, please visit https://clickholdings.com.hk.

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For enquiry, please contact:

Click Holdings Limited

Unit 1709-11, 17/F
Tower 2, The Gateway
Harbour City, Kowloon
Hong Kong
Email: jack.wong@jfy.hk
Phone: +852 2691 8200 

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has entered into agreements to partner with Wittington Investments, Limited (“Wittington”), the holding company of the Weston family based in Canada, to acquire The Boots Group (“Boots”), the leading pharmacy and health and beauty retailer in the United Kingdom and Ireland, for a total purchase price of approximately US$8.9 billion (inclusive of assumed debt) (the “Transaction”).

“We are very pleased to partner with Galen Weston and the Wittington team to acquire Boots, a leading historic brand in the United Kingdom and Ireland,” said Prem Watsa, Chairman and Chief Executive Officer of Fairfax. “For many years, the Westons have grown and developed some of the most successful retail brands in Canada, including in pharmacy and beauty, and we are very confident that Wittington, with its experienced and capable management group, will be an excellent steward of the Boots business and a terrific partner to Fairfax.”

“Boots is one of Britain’s most enduring businesses with a rich heritage, a trusted name and a vital role in everyday life across the UK and Ireland,” said Galen Weston. “We have great respect for Boots’ legacy and leading market position. We see a meaningful opportunity to make a great business even better, through stable, long-term ownership, capital investment and renewed operating focus required to serve customers with excellence for generations to come. We are delighted to partner with Fairfax who brings an extensive track record of long-term investing and ownership in leading retail brands, and who shares our conviction in both building great businesses and in Boots’ future.”

In connection with the Transaction, Fairfax entered into an equity commitment letter pursuant to which it has agreed to provide, or cause an affiliate of it to provide, up to approximately US$2.3 billion for the purposes of satisfying the purchase price to be paid for Boots. Following the closing of the Transaction, it is expected that Fairfax will own 50% of the equity of Boots, with Wittington having operational control and Galen Weston serving as Chair of Boots. The Transaction is subject to customary closing conditions and is expected to be completed in the first quarter of 2027. The transaction does not include Boots’ businesses in Germany and Mexico which will be retained by their current owner.

Wittington Investments, Limited is the private holding company for the Weston family based in Canada. It is the controlling shareholder of George Weston Limited – and through it, Loblaw Companies Limited and Choice Properties. With more than 2,800 locations, Loblaw is Canada’s largest grocery retailer and owns Shopper Drug Mart, the nation’s largest pharmacy, health and beauty business. Choice Properties, Canada’s largest Real Estate Investment Trust (REIT), has a portfolio comprised of approximately 700 high-quality properties across three strategic asset classes, including 44.6 million square feet of necessity-based retail.

Fairfax is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management.

For further information contact:	John Varnell, Vice President, Corporate Development at (416) 367-4941

Certain statements contained herein may constitute “forward-looking statements” and are made pursuant to the “safe harbour” provisions of applicable Canadian and U.S. securities laws. Such forward-looking statements may include, among other things, statements regarding the Transaction, the timing of completion thereof and expectations regarding future performance of Boots. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Fairfax to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the failure to successfully complete the Transaction on the terms and timeframes contemplated; our ability to complete acquisitions and other strategic transactions on the terms and timeframes contemplated, and to achieve the anticipated benefits therefrom; a reduction in net earnings if our loss reserves are insufficient; underwriting losses on the risks we insure that are higher than expected; the occurrence of catastrophic events with a frequency or severity exceeding our estimates; changes in market variables, including unfavourable changes in interest rates, foreign exchange rates, equity prices and credit spreads, which could negatively affect our operating results and investment portfolio; the cycles of the insurance market and general economic conditions, which can substantially influence our and our competitors’ premium rates and capacity to write new business; insufficient reserves for asbestos, environmental and other latent claims; exposure to credit risk in the event our reinsurers fail to make payments to us under our reinsurance arrangements; exposure to credit risk in the event our insureds, insurance producers or reinsurance intermediaries fail to remit premiums that are owed to us or failure by our insureds to reimburse us for deductibles that are paid by us on their behalf; our inability to maintain our long term debt ratings, the inability of our subsidiaries to maintain financial or claims paying ability ratings and the impact of a downgrade of such ratings on derivative transactions that we or our subsidiaries have entered into; risks associated with implementing our business strategies; the timing of claims payments being sooner or the receipt of reinsurance recoverables being later than anticipated by us; risks associated with any use we may make of derivative instruments; the failure of any hedging methods we may employ to achieve their desired risk management objective; a decrease in the level of demand for insurance or reinsurance products, or increased competition in the insurance industry; the impact of emerging claim and coverage issues or the failure of any of the loss limitation methods we employ; our inability to access cash of our subsidiaries; an increase in the amount of capital that we and our subsidiaries are required to maintain and our inability to obtain required levels of capital on favourable terms, if at all; the loss of key employees; our inability to obtain reinsurance coverage in sufficient amounts, at reasonable prices or on terms that adequately protect us; the passage of legislation subjecting our businesses to additional adverse requirements, supervision or regulation, including additional tax regulation, in the United States, Bermuda, Canada or other jurisdictions in which we operate; risks associated with applicable laws and regulations relating to sanctions, anti-money laundering and corrupt practices in Canada and in foreign jurisdictions in which we operate; risks associated with government investigations of, and litigation and negative publicity related to, insurance industry practice or any other conduct; risks associated with political and other developments in foreign jurisdictions in which we operate; risks associated with legal or regulatory proceedings or significant litigation; failures or security breaches of our computer and data processing systems; the influence exercisable by our significant shareholder; adverse fluctuations in foreign currency exchange rates; our dependence on independent brokers over whom we exercise little control; financial reporting risks relating to deferred taxes associated with amendments to IAS 12 – Income Taxes; impairment of the carrying value of our goodwill, indefinite-lived intangible assets or investments in associates; our failure to realize deferred income tax assets; risks associated with Canadian or foreign tax laws, or the interpretation thereof; technological or other change that adversely impacts demand, or the premiums payable, for the insurance coverages we offer; disruptions of our information technology systems; assessments and shared market mechanisms that may adversely affect our insurance subsidiaries; risks associated with economic disruptions from global conflicts and the development of other geopolitical events worldwide; and risks associated with tariffs, trade restrictions, or other regulatory measures imposed by domestic or foreign governments that may, directly or indirectly, affect our business. Additional risks and uncertainties are described in our most recently issued Annual Report, which is available at www.fairfax.ca and on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov, and in our base shelf prospectus (under “Risk Factors”) filed with the securities regulatory authorities in Canada, which is available on SEDAR+ at www.sedarplus.ca. Fairfax disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

SOUDERTON, Pa., Oct. 07, 2026 (GLOBE NEWSWIRE) — Univest Financial Corporation (Nasdaq: UVSP), parent company of Univest Bank and Trust Co. and its insurance, investment and equipment finance subsidiaries, announced it will host a conference call to discuss its third quarter 2026 earnings on Thursday, October 29, 2026 at 9:00 a.m. Earnings are scheduled to be released after the close of the market on Wednesday, October 28, 2026.

Pre-registration
Telephone participants may avoid any delays by pre-registering for the call using the following link.

Conference Call registration link: https://registrations.events/direct/Q4I37740VIPBmQSGdfZvAKstK

Audio
Dial in number: 1-800-715-9871
Note: Participants who are unable to pre-register should dial in a few minutes prior to the start time.
*Please mention Conference ID 37740 or “Univest Financial Corporation Third Quarter 2026 Earnings Call” to the operator.

Replay
Link: https://registrations.events/direct/Q4I37740VIPBmQSGdfZvAKstK
Available until: November 5, 2026

About Univest Financial Corporation
Univest Financial Corporation (UVSP), including its wholly-owned subsidiary Univest Bank and Trust Co., Member FDIC, has approximately $8.2 billion in assets and $6.2 billion in assets under management and supervision through its Wealth Management lines of business at June 30, 2026. Headquartered in Souderton, Pa. and founded in 1876, the Corporation and its subsidiaries provide a full range of financial solutions for individuals, businesses, municipalities and nonprofit organizations primarily in the Mid-Atlantic Region. Univest delivers these services through a network of more than 50 offices and online at www.univest.net.

CONTACT: Contact:
Brian J. Richardson
Univest Financial Corporation
Chief Financial Officer
215-721-2446 | richardsonb@univest.net

Golar LNG Limited (NASDAQ: GLNG) (“Golar” or “the Company”) announces today that it has agreed to acquire the LNG carrier Grace Dahlia from NYK Line. The Grace Dahlia was built in 2013 and has been maintained and managed to the highest operational standards by NYK Line.

The vessel is intended to be used for conversion into Golar’s fourth FLNG (“FLNG #4”) ordered on August 12, 2026. Grace Dahlia has an LNG storage capacity of 177,427cbm, providing FLNG #4 with approximately 20% larger storage capacity compared to the 3.5MTPA FLNG Esperanza currently under construction. The larger storage capacity will provide prospective FLNG customers with additional offloading flexibility while retaining the benefits to Golar of a repeat MKII design. The FLNG #4 will be converted alongside FLNG Esperanza at CIMC Raffles’ Yantai shipyard in China. With redelivery scheduled for 2029, FLNG #4 represents the world’s earliest available FLNG capacity.

FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negative of these terms and similar expressions are intended to identify such forward-looking statements.

These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Golar LNG Limited undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable law.

Hamilton, Bermuda
October 7, 2026
Investor Questions: +44 207 063 7900
Karl Fredrik Staubo – CEO
Eduardo Maranhão – CFO

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act